How to navigate EU MAA Regulations and Registration Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter this market it is critical to ass...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Dublin clinical trials group ICON buys PRA in $12bn deal
The combined company will form the world’s largest contract research organisation, and is to be headquartered at ICON’s Leopardstown campus in Dublin.
-
In the biggest CRO takeover in years, ICON doles out $12B for PRA Health Sciences to focus on decentralised clinical work
ICON will acquire PRA Health Sciences for $12 billion in a move that will shake up the hightest rungs of a fragmented market.
-
Deal watch: ICON, PRA Health form massive CRO In $12bn merger
ICON acquires PRA Health Sciences to form a world-leader CRO.
-
ICON eyes growing virtual clinical trial market with $12 bln PRA Health deal
An article reporting on ICON's acquisition of contract research organisation PRA Health Sciences.
-
COVID trials vaccine firm ICON announces €10bn US takeover deal
ICON has announced one of the biggest takeover deals in Irish corporate history.
-
ICON to buy contract researcher PRA Health for $12B
ICON will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.
-
ICON plc acquires PRA Health Sciences Inc. in $12 billion acquisition
In a cash and stock transaction value of approximately $12 billion, ICON plc has announced its acquisition of PRA Health Sciences as part of a focus on innovative and high-quality clinical trials.
-
CRO consolidation continues with ICON buying PRA Health Sciences for $12B
ICON is set to acquire rival PRA Health Sciences in a $12 billion deal that will vault the combined company into second place among clinical trial services providers.
-
How to manage the impact of COVID-19 on IVDR timelines
Angela Brown and Nicole A. Cowan, Director examine how IVD manufacturers can meet 2022 deadlines despite the COVID-19 pandemic.
-
Decentralised, hybrid or traditional: Choosing the best option for your clinical trial
In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.
